Published in Cancer Weekly, April 7th, 2009
"A resistant HCC cell line (QGY/CDDP) was established by stepwise increasing cisplatin (CDDP) concentration and intermittent administration. Drug-chemo sensitivity was detected by 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cell doubling time was determined by cell...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.